PPLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.5
| Stock Code | PPLPHARMA | Market Cap | 21,517 Cr. | Current Price | 162 ₹ | High / Low | 226 ₹ |
| Stock P/E | 29.2 | Book Value | 58.2 ₹ | Dividend Yield | 0.09 % | ROCE | 12.4 % |
| ROE | 9.74 % | Face Value | 10.0 ₹ | DMA 50 | 154 ₹ | DMA 200 | 173 ₹ |
| Chg in FII Hold | 0.51 % | Chg in DII Hold | -0.07 % | PAT Qtr | 151 Cr. | PAT Prev Qtr | 196 Cr. |
| RSI | 61.5 | MACD | 4.52 | Volume | 36,50,670 | Avg Vol 1Wk | 67,00,136 |
| Low price | 132 ₹ | High price | 226 ₹ | PEG Ratio | 1.31 | Debt to equity | 0.12 |
| 52w Index | 31.6 % | Qtr Profit Var | 27.4 % | EPS | 5.39 ₹ | Industry PE | 30.1 |
Chart Patterns & Moving Averages: PPLPHARMA is trading above its 50 DMA (₹154) but below its 200 DMA (₹173), showing short-term strength but medium-term weakness. Price action indicates support near ₹160–₹162 and resistance around ₹170–₹175.
RSI & Momentum: RSI at 61.5 reflects moderately bullish momentum. MACD at 4.52 is positive, suggesting short-term upward bias.
Bollinger Bands: Price is mid-to-upper band, reflecting momentum but limited breakout strength.
Volume Trends: Current volume (36.5L) is below average (67.0L), showing reduced participation and weakening conviction.
Entry/Exit Zones:
- **Entry:** ₹160–₹162 (near support zone)
- **Exit:** ₹170–₹175 (resistance zone)
- **Stop-loss:** ₹158 (below support)
Trend Status: Consolidation with mild bullish bias; reversal signals absent but fundamentals provide moderate stability.
Positive
- EPS at ₹5.39 remains positive.
- PEG ratio at 1.31 indicates fair valuation relative to growth.
- ROCE (12.4%) and ROE (9.74%) reflect moderate profitability.
- Debt-to-equity ratio low (0.12), showing balance sheet stability.
- FII holding increased (+0.51%).
Limitation
- Price below 200 DMA reflects medium-term weakness.
- Volume significantly below average, limiting breakout conviction.
- Dividend yield negligible (0.09%).
- Profitability metrics modest compared to peers.
Company Negative News
- PAT declined from ₹196 Cr to ₹151 Cr.
- DII holding decreased (-0.07%).
- Weak technical momentum despite fair valuation.
Company Positive News
- Quarterly profit variation positive (+27.4%).
- FII inflows show foreign institutional confidence.
- Price recovery potential from 52-week low (₹132).
Industry
- Industry PE at 30.1, slightly higher than PPLPHARMA’s valuation, making it relatively attractive.
- Pharma sector supported by global demand but competitive pressures remain.
- Peers offer stronger fundamentals and higher ROE/ROCE.
Conclusion
PPLPHARMA is consolidating with weak technical momentum but fair valuation and moderate fundamentals. Entry near ₹160–₹162 offers limited upside toward ₹170–₹175, but strict stop-loss discipline at ₹158 is essential. Suitable for cautious swing trades; long-term investors should remain selective until technical strength improves.
This HTML report captures PPLPHARMA’s consolidation phase with modest fundamentals and tactical entry/exit zones. Would you like me to add a sector overlay comparing PPLPHARMA with peers like Sun Pharma, Lupin, and Aurobindo Pharma to highlight relative strength and valuation positioning?